Biognosys and Alamar Biosciences Forge Strategic Partnership in Proteomics to Advance Biopharma and Precision Medicine Research
04 Abril 2024 - 9:11AM
Biognosys, a global leader in mass spectrometry-based proteomics,
and Alamar Biosciences, Inc., a company powering precision
proteomics to enable the earliest detection of disease, are pleased
to announce a strategic partnership aimed at advancing scientific
discovery in the field of biofluid proteomics biomarkers. This
collaboration brings together Biognosys’ expertise in unbiased
discovery through data independent acquisition mass spectrometry
(DIA-MS) and Alamar’s cutting-edge immunoassays. This integrated
approach enhances our understanding of biomarkers by combining deep
unbiased DIA-MS discovery proteomics with highly specific and
ultra-sensitive mid- and high-plex NULISA assays for low-abundance
proteins such as cytokines, chemokines and important disease
protein biomarkers from plasma.
In the Industry Spotlight Theater session hosted by
Alamar at the American Society for Cancer Research (AACR) 2024
Annual Meeting in San Diego on April 9 at 12:30 pm PT, the
companies will jointly present data from a collaborative study
focused on Non-Small Cell Lung Cancer (NSCLC). In this study,
plasma samples from a cohort of NSCLC patients were analyzed using
both the Biognosys TrueDiscovery® unbiased discovery platform and
Alamar’s NULISAseq™ Inflammation Panel 250. The findings
demonstrate the feasibility of integrated analysis and highlight
the complementary insights derived from mass spectrometry and
affinity-based assays in plasma.
Building upon this successful proof-of-concept
study, Biognosys and Alamar are planning to further collaborate
both commercially and scientifically as part of their strategic
partnership.
- NULISA Assay Services:
Biognosys will offer NULISA assays from its state-of-the-art
facility in Switzerland for previously hard to measure cytokines,
chemokines, as well as other important disease specific markers
from plasma and biofluids. These ultra-high sensitivity assays
enable precise quantification of low abundance proteins, providing
researchers with valuable insights into complex biological
processes. They complement unbiased DIA-MS analysis of thousands of
plasma proteins to elucidate systemic host response, and other
inflammation or disease-related protein-fold changes.
- Research
Collaboration: Biognosys and Alamar will embark on a joint
research initiative to explore plasma biology. By leveraging
Biognosys’ unbiased discovery methods alongside Alamar’s ultra-high
sensitivity assays, the teams seek to unravel biological disease
mechanisms by providing a more complete picture of the plasma
proteome, enabling for the first time the coverage of essentially
the complete dynamic range of protein abundance in plasma.
Oliver Rinner, Ph.D., Founder and CEO of
Biognosys, expressed enthusiasm about the collaboration:
“We are excited to join forces with Alamar to advance proteomics
research. Our combined efforts will pave the way for breakthroughs
in plasma biology by analyzing in an unbiased way more than 5,000
proteins together with panels of hundreds of well characterized
cytokines and other high value low abundance proteins using highly
specific NULISA assays. With this approach we are aiming to cover
the whole dynamic range of plasma proteins.”
“We are thrilled to partner with Biognosys to
provide the research community with expanded access to proteomic
insights from discovery through to clinical research,” said
Yuling Luo, Ph.D., Chairman, Founder and CEO of
Alamar. “Biognosys is a leading provider of advanced mass
spec proteomics services to researchers around the world, and we
look forward to adding the highest sensitivity high-multiplex
immunoassays to their plasma proteomics offering.”
This partnership underscores the commitment of both
companies to scientific excellence and their shared vision of
advancing precision medicine through innovative technologies.
Biognosys’ DIA mass spectrometry unbiased
proteomics platform
Biognosys’ DIA proteomics analysis
software, Spectronaut®
Alamar’s NULISA™ platform: a new
standard in proteomic analysis
A Media Snippet accompanying this announcement is
available by clicking on this link.
About Biognosys
At Biognosys, we believe that deep proteome
insights hold the key to breakthrough discoveries that transform
science for better lives. With our versatile portfolio of
next-generation proteomics solutions, including the TrueDiscovery®,
TrueTarget®, and TrueSignature® research service platforms, our
flagship software Spectronaut®, and the PQ500™ kit, we make the
proteome actionable to empower research, drug development, and
clinical decision-making. Our solutions provide a multi-dimensional
view of protein expression, function, and structure in all
biological species and sample types. Our unique, patented
technologies utilize high-resolution mass spectrometry to quantify
thousands of proteins with industry-leading precision, depth, and
throughput. Through our strategic partnership with Bruker (Nasdaq:
BRKR), we make proteomics globally accessible. For more
information, visit biognosys.com.
About AlamarAlamar Biosciences is
a privately held life sciences company with a mission to power
precision proteomics to enable the earliest detection of disease.
The company’s proprietary NULISA Platform along with the ARGO™ HT
System work seamlessly with the latest advances in genomics to
achieve single digit attomolar detection sensitivity, greatly
surpassing the most sensitive protein detection technology on the
market today. For more information, please visit alamarbio.com.
Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/b9485cd0-929f-48e9-b405-efdfbf7b5caa
https://www.globenewswire.com/NewsRoom/AttachmentNg/5eabe48a-06b5-4c37-8181-d5ff5a41a1cb
Contacts
Biognosys AG
Yves Serroen
Phone +41 (0) 44 244 50 07
yves.serroen@biognosys.com
Alamar Biosciences, Inc
Media contact:
April Falcone
Phone +1 (510) 838-1783
afalcone@alamarbio.com
Investor contact:
investors@alamarbio.com
Bruker (NASDAQ:BRKR)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Bruker (NASDAQ:BRKR)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024